Nicotine exerts many of its behavioral effects through a diverse family of nicotinic acetylcholine receptors. In particular, nicotine evoked dopamine release is thought to play an important role in the establishment and maintenance of nicotine dependence. alpha-Conotoxin MII is a recently-discovered toxin, isolated from the predatory cone snail Conus magus, which blocks alpha3-beta2subtype nicotinic receptors with high potency and selectivity. Alpha-Conotoxin MII also selectively and potently blocks measures of nicotine evoked dopamine release in vitro, and may thus be a tool with which to explore a behaviorally significant nicotinic receptor subtype. Both native and radiolabeled ([125I]-alphaCtx MII) alpha-conotoxin MII are available and will be used to characterize a-conotoxin MII bindings sites. We intend to test the native toxin against [3H]epibatidine binding (at alpha3beta2-transfected cell and mouse brain preparations) and measures of nicotinic activation in vitro. [125]alphaCtx MII binding will be used to characterize both transfected cell and centrally expressed receptors, using biochemical and autoradiographic techniques. These studies are intended to define the numbers, distribution and function of alpha-conotoxin MII sites in the mammalian (mouse) CNS. Comparison of the sites expressed in the cell line with those in brain will determine how similar the native and model sites are. In addition, we will attempt to develop a further set of probes based on alpha-conotoxin MII incorporating photoactivatable and biotinyl tags into the toxin's primary peptide sequence. These probes are designed to allow the exploration of alpha-conotoxin MII bindings sites' composition and structure. The proposed studies will provide insights into the nature and importance of a novel, native nicotinic receptor. Hopefully, this knowledge will lead to a better understanding of the basis (of) nicotine's centrally mediated effects, and may lead to the development of improved nicotinic drugs and/or treatments for nicotine dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA012242-03
Application #
6350525
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Hillery, Paul
Project Start
1999-02-01
Project End
2002-06-30
Budget Start
2001-02-01
Budget End
2002-06-30
Support Year
3
Fiscal Year
2001
Total Cost
$213,945
Indirect Cost
Name
University of Colorado at Boulder
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
City
Boulder
State
CO
Country
United States
Zip Code
80309
Lucero, Linda M; Weltzin, Maegan M; Eaton, J Brek et al. (2016) Differential ?4(+)/(-)?2 Agonist-binding Site Contributions to ?4?2 Nicotinic Acetylcholine Receptor Function within and between Isoforms. J Biol Chem 291:2444-59
Marks, Michael J; O'Neill, Heidi C; Wynalda-Camozzi, Kelly M et al. (2015) Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology 99:142-55
Hone, Arik J; McIntosh, J Michael; Azam, Layla et al. (2015) ?-Conotoxins Identify the ?3?4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells. Mol Pharmacol 88:881-93
Eaton, J Brek; Lucero, Linda M; Stratton, Harrison et al. (2014) The unique ?4+/-?4 agonist binding site in (?4)3(?2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (?4)2(?2)3 subtype. J Pharmacol Exp Ther 348:46-58
Marks, Michael J; Grady, Sharon R; Salminen, Outi et al. (2014) ?6?2*-subtype nicotinic acetylcholine receptors are more sensitive than ?4?2*-subtype receptors to regulation by chronic nicotine administration. J Neurochem 130:185-98
Luo, Sulan; Zhangsun, Dongting; Schroeder, Christina I et al. (2014) A novel ?4/7-conotoxin LvIA from Conus lividus that selectively blocks ?3?2 vs. ?6/?3?2?3 nicotinic acetylcholine receptors. FASEB J 28:1842-53
Wang, Yuexiang; Lee, Jang-Won; Oh, Gyeon et al. (2014) Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function ?6* nAChRs. J Neurochem 129:315-27
Soll, Lindsey G; Grady, Sharon R; Salminen, Outi et al. (2013) A role for *4(non-*6)* nicotinic acetylcholine receptors in motor behavior. Neuropharmacology 73:19-30
Marks, Michael J (2013) Genetic matters: thirty years of progress using mouse models in nicotinic research. Biochem Pharmacol 86:1105-13
O'Neill, Heidi C; Laverty, Duncan C; Patzlaff, Natalie E et al. (2013) Mice expressing the ADNFLE valine 287 leucine mutation of the ?2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function. Pharmacol Biochem Behav 103:603-21

Showing the most recent 10 out of 78 publications